Although still in its infancy, this technology has already shown remarkable effectiveness in detecting and treating cancer, ...

The FDA and NIH recently announced plans to phase out animal testing requirements for some therapies. While organoid and AI ...

The global AI In Healthcare Market size is projected to be valued at USD 26.6 Billion in 2024 and reach USD 187.7 billion by 2030, growing at ...

From easing clinician workloads to enabling faster, smarter diagnoses, these practical AI tools are transforming healthcare ...

Lantern Pharma's Q1 2025 earnings reveal clinical progress, AI commercialization plans, and financial discipline.

The increasing incidence of infectious and chronic illnesses is boosting the need for early and precise diagnosis, with AI playing a crucial role by ...

The annual analysis documented approvals of 18 new personalized medicines in 2024, important regulatory milestones and establishment of the Center fo ...

GE HealthCare (Nasdaq: GEHC) today announced the launch of its CleaRecon DL technology for enhancing CBCT imaging.

Stuart J. Schnitt, MD, discussed how AI enhances cancer diagnoses and the need for professional oversight, ethical clarity, and equitable adoption.

We recently published a list of the 10 Most Popular AI Stocks to Avoid Now. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc.

Monogram Technologies Inc (MGRM) secures FDA clearance for its TKA system, while navigating competitive pressures and planning a strategic rollout.